
1. Technology overview
Noul Co., Ltd. is a medical diagnostics company established in 2015 and headquartered in Yongin, Gyeonggi-do, South Korea. It develops AI-based digital microscopy so that blood, malaria and cervical cell tests can be read at the point of care without a specialist pathologist. The company has been listed on KOSDAQ since 2022.
The miLab platform combines a compact staining and imaging device, single-use cartridges and AI analysis software. Three solutions run on it: miLab MAL for malaria, miLab BCM for complete blood count and cell morphology, and miLab CER for cervical cancer cytology. It is sold to hospitals, laboratories and public health programs through distributors, including supply to the Charite university hospital in Germany.
2. Highlighted features & specifications
- miLab MAL: digital microscope that analyses malaria samples.
- miLab BCM: automated complete blood count and cell morphology analysis.
- miLab CER: AI cytology for early detection of cervical cancer.
- Cartridge workflow: single-use cartridges with SafeFix reagent for staining and clearing.
- AI reading: expert-level cell classification on captured images.
3. Potential application
Provincial and district hospitals in Vietnam can use miLab CER for cervical cancer screening programs. Clinical laboratories and private clinics can use miLab BCM for blood count with morphology review. Public health programs in malaria-risk areas can deploy miLab MAL.
4. Benefits
- Brings blood and cervical cell analysis to sites without a specialist pathologist.
- Single-use cartridges and a compact device simplify laboratory workflow.
- The cervical solution miLab CER was named in the 2024 WHO-Unitaid report as one of three recommended triage technologies.
- Holds CE marking, Korean MFDS approval and ISO 13485 certification.
5. Market trends & opportunities
Cervical cancer screening and decentralised laboratory testing are expanding as health systems seek point-of-care tools that reduce dependence on scarce pathologists. Noul reports that its cervical solution has received clearance in Vietnam, which signals demand for such tools in Southeast Asia.
6. Other information
Founded 2015, Yongin, South Korea. KOSDAQ IPO in 2022. CE marking 2021-2022, ISO 13485 in 2018, Korean MFDS approval 2019. Series B USD 13.9 million in 2020. Exclusive distribution with Limbach Group (Germany) in 2024; supply to Charite announced October 2025.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































